Health-care companies fell as traders hedged their bets on the outlook for growth in the sector.

The U.S. Food and Drug Administration is investigating certain CAR T cancer immunotherapies based on reports that they might cause a type of white blood cell to become cancerous in patients who received the treatment. Shares of Cabaletta Bio fell following the report.

Treatments made by Novartis, Johnson & Johnson and Gilead Sciences, among others, could also be affected.

Write to Rob Curran at

(END) Dow Jones Newswires

11-28-23 1727ET